Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

In order to boost immune responses in persons in whom highly active antiretroviral therapy (HAART) was initiated within 120 days of the onset of symptoms of newly acquired human immunodeficiency virus type 1 (HIV-1) infection, we administered vaccines containing a canarypox virus vector, vCP1452, wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jin, Xia, Ramanathan, Jr., Murugappan, Barsoum, Shady, Deschenes, Geoffrey R., Ba, Lei, Binley, James, Schiller, Daryl, Bauer, Daniel E., Chen, Donald C., Hurley, Arlene, Gebuhrer, Lucette, El Habib, Raphaelle, Caudrelier, Pierre, Klein, Michel, Zhang, Linqi, Ho, David D., Markowitz, Martin
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2002
Matèries:
Vaccines and Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC135946/
https://ncbi.nlm.nih.gov/pubmed/11836398
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars